# Acadia Pharmaceuticals (ACAD) — Earnings

ACAD · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/acad/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.18 |
| EPS estimate | $0.06 |
| EPS surprise | +210.34% |
| Revenue surprise | +4.21% |
| Revenue | $308.0M |
| Revenue estimate | $295.5M |
| Reported | Aug 4, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1070494/000119312526333243/acad-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/7d0d4886-21a4-f742-0bb9-f6630569f42e.html) |

Acadia Pharmaceuticals reported Q2 2026 results on August 4, 2026. Earnings per share were $0.18, well above the $0.06 estimate, a 210.34% beat. Revenue of $308.0 million topped the $295.5 million consensus by 4.21%. Compared with Q2 2025, EPS rose from $0.16 and revenue grew about 16% from $264.6 million. Revenue was the highest quarterly figure in the table.

The table shows a shift from losses to profits. Acadia lost money in eight quarters between Q3 2021 and Q3 2023, including full-year losses of $1.34 per share in 2022 and $0.38 in 2023. Every quarter since Q4 2023 has been profitable. Annual EPS reached $1.36 in 2024 and $2.29 in 2025, while yearly revenue more than doubled from $517.3 million in 2022 to $1.07 billion in 2025. Q4 2025 EPS of $1.60 was the high in the table. The first half of 2026 totaled $0.20, against $0.27 a year earlier. Acadia beat EPS estimates in 14 of the last 20 quarters.

Q3 results came out between November 2 and November 8 in each of the past five years. That points to early November 2026 for the next report, which will show whether recent revenue growth continues.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 4, 2026 | $0.06 | $0.18 | 210.34% | $295.5M | $308.0M |
| Q1 2026 | May 6, 2026 | $0.05 | $0.02 | -60.40% | $280.3M | $268.1M |
| Q4 2025 | Feb 25, 2026 | $0.14 | $1.60 | 1067.88% | $292.8M | $284.0M |
| Q3 2025 | Nov 5, 2025 | $0.17 | $0.42 | 142.91% | $276.5M | $278.6M |
| Q2 2025 | Aug 6, 2025 | $0.14 | $0.16 | 15.86% | $262.0M | $264.6M |
| Q1 2025 | May 7, 2025 | $0.09 | $0.11 | 26.87% | $238.8M | $244.3M |
| Q4 2024 | Feb 26, 2025 | $0.22 | $0.86 | 298.70% | $255.6M | $259.6M |
| Q3 2024 | Nov 6, 2024 | $0.14 | $0.20 | 44.82% | $248.8M | $250.4M |
| Q2 2024 | Aug 6, 2024 | $0.18 | $0.20 | 12.55% | $235.9M | $242.0M |
| Q1 2024 | May 8, 2024 | $0.05 | $0.10 | 104.92% | $208.3M | $205.8M |
| Q4 2023 | Feb 27, 2024 | $0.29 | $0.28 | -3.08% | $223.8M | $231.0M |
| Q3 2023 | Nov 2, 2023 | −$0.45 | −$0.40 | 10.65% | $192.3M | $211.7M |
| Q2 2023 | Aug 2, 2023 | −$0.10 | $0.01 | 110.22% | $166.2M | $165.2M |
| Q1 2023 | May 8, 2023 | −$0.21 | −$0.27 | -25.87% | $120.1M | $118.5M |
| Q4 2022 | Feb 28, 2023 | −$0.25 | −$0.26 | -5.22% | $134.2M | $136.5M |
| Q3 2022 | Nov 2, 2022 | −$0.19 | −$0.17 | 12.46% | $138.8M | $130.7M |
| Q2 2022 | Aug 8, 2022 | −$0.25 | −$0.21 | 15.25% | $130.4M | $134.6M |
| Q1 2022 | May 4, 2022 | −$0.62 | −$0.70 | -13.29% | $121.9M | $115.5M |
| Q4 2021 | Feb 28, 2022 | −$0.24 | −$0.27 | -13.64% | $135.4M | $130.8M |
| Q3 2021 | Nov 8, 2021 | −$0.26 | −$0.09 | 65.32% | $127.9M | $131.6M |

## Frequently Asked Questions

### When did Acadia Pharmaceuticals (ACAD) last report earnings?

Acadia Pharmaceuticals last reported on Aug 4, 2026, covering fiscal Q2 2026.

### Did ACAD beat earnings estimates?

Yes. Acadia Pharmaceuticals reported EPS of $0.18 for Q2 2026 against a $0.06 estimate — a 210.34% beat.

### How much revenue did ACAD report last quarter?

Acadia Pharmaceuticals reported $308.0M in revenue for Q2 2026, against a consensus estimate of $295.5M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).